

Dominik Samotij

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5551487/publications.pdf>

Version: 2024-02-01

21
papers

237
citations

1162889

8
h-index

996849

15
g-index

22
all docs

22
docs citations

22
times ranked

307
citing authors

#	ARTICLE	IF	CITATIONS
1	The "Connective Tissue Diseases", 2022, , 357-420.		0
2	Chronic Plaque Psoriasis in Poland: Disease Severity, Prevalence of Comorbidities, and Quality of Life. Journal of Clinical Medicine, 2022, 11, 1254.	1.0	9
3	The Analysis of a Genome-Wide Association Study (GWAS) of Overweight and Obesity in Psoriasis. International Journal of Molecular Sciences, 2022, 23, 7396.	1.8	8
4	Acrodermatitis Continua of Hallopeau Evolving into Generalized Pustular Psoriasis Following COVID-19: A Case Report of a Successful Treatment with Infliximab in Combination with Acitretin. Biologics: Targets and Therapy, 2021, Volume 15, 107-113.	3.0	12
5	Clinical characteristics of itch in cutaneous lupus erythematosus: A prospective, multicenter, multinational, cross-sectional study. Lupus, 2021, 30, 096120332110160.	0.8	7
6	Pathogenesis of psoriasis in the "omicron" era. Part II. Genetic, genomic and epigenetic changes in psoriasis. Postepy Dermatologii I Alergologii, 2020, 37, 283-298.	0.4	29
7	Pathogenesis of psoriasis in the "omicron" era. Part III. Metabolic disorders, metabolomics, nutrigenomics in psoriasis in psoriasis. Postepy Dermatologii I Alergologii, 2020, 37, 452-467.	0.4	26
8	Pathogenesis of psoriasis in the "omicron" era. Part I. Epidemiology, clinical manifestation, immunological and neuroendocrine disturbances. Postepy Dermatologii I Alergologii, 2020, 37, 135-153.	0.4	28
9	The "Connective Tissue Diseases", 2020, , 1-64.		0
10	Quality of Life in Patients with Morphea: A Cross-Sectional Study and a Review of the Current Literature. BioMed Research International, 2020, 2020, 1-8.	0.9	8
11	Pathogenesis of psoriasis in the "omicron" era. Part IV. Epidemiology, genetics, immunopathogenesis, clinical manifestation and treatment of psoriatic arthritis. Postepy Dermatologii I Alergologii, 2020, 37, 625-634.	0.4	8
12	Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review. BioMed Research International, 2019, 2019, 1-17.	0.9	41
13	Rheumatoid neutrophilic dermatitis. Reumatologia, 2019, 57, 350-353.	0.5	3
14	Slowly Progressing Asymptomatic Disseminated Telangiectasias: A Quiz. Acta Dermato-Venereologica, 2018, 98, 820-821.	0.6	1
15	Paraneoplastic systemic sclerosis associated with colorectal carcinoma. Reumatologia, 2018, 56, 194-198.	0.5	5
16	Disease severity and prophylactic measures in patients with cutaneous lupus erythematosus: results of a worldwide questionnaire-based study. Postepy Dermatologii I Alergologii, 2018, 35, 192-198.	0.4	5
17	Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional Study. BioMed Research International, 2018, 2018, 1-5.	0.9	11
18	Biologics for Itch: IL-4/IL-13, IL-31, IL-17, and IL-23 Antagonists. Current Dermatology Reports, 2017, 6, 263-272.	1.1	3

#	ARTICLE	IF	CITATIONS
19	Carcinoma en cuirasse as an initial manifestation of inflammatory breast cancer. Postepy Dermatologii I Alergologii, 2016, 2, 142-145.	0.4	13
20	Clinical characteristics of cutaneous lupus erythematosus. Postepy Dermatologii I Alergologii, 2016, 1, 13-17.	0.4	16
21	Erythema gyratum repens associated with cryptogenic organizing pneumonia. Indian Journal of Dermatology, Venereology and Leprology, 2016, 82, 212.	0.2	4